Risks

Long receivable and inventory cycles versus peers can keep cash conversion elevated, limiting working-capital flexibility if demand softens or reimbursement timing slips.

Moderate leverage with net debt to EBITDA near 1.3x versus many healthcare peers supports balance-sheet resilience, but still leaves less cushion than net-cash competitors in a downturn.

Interest coverage above 20x materially reduces refinancing pressure versus leveraged peers, yet higher rates could still compress free cash flow if operating momentum weakens.

A current ratio above 1.6x and quick ratio above 1.0x indicate adequate liquidity versus tighter peers, but they do not fully offset the drag from slow cash realization.

Opportunities

High interest coverage and modest leverage versus more indebted peers preserve financial flexibility, supporting continued investment in growth and resilience through the cycle.

Liquidity metrics above 1.0x on the quick ratio and 1.6x on the current ratio compare favorably with weaker peers, reducing near-term funding risk.

If demand remains stable, the company’s manageable debt load versus highly levered peers can translate into steadier earnings durability and less balance-sheet volatility.

Compared with peers facing tighter liquidity or heavier refinancing needs, STVN is better positioned to absorb working-capital swings without forcing disruptive capital actions.

Overall Score

STVN’s forward positioning is supported by solid liquidity and low interest burden versus peers, while elevated working-capital intensity and only moderate leverage keep risks manageable but relevant.